1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...
Seeking Alpha on MSN5d
Eli Lilly snaps six straight sessions of losses
Earlier in October, Eli Lilly missed on both the top and bottom lines in its Q3 financial results, but its sales grew 20%, ...
tyla16h
Company behind weight loss drug Mounjaro issues statement as first Brit dies after using jab twice
Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...
Zacks.com on MSN1d
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
Hong Kong approves celebrity weight-loss drug, but experts say it’s not just to look good
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...
Moneyweb1h
Meds regulator warns against ‘fake’ Ozempic-like products
GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...
Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...
Eli Lilly and Company (LLY): Ken Fisher’s Bet on a Pharma Giant’s Growth Potential
We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...